-
公开(公告)号:EP3656791A1
公开(公告)日:2020-05-27
申请号:EP18836123.2
申请日:2018-07-18
发明人: KAI, Masayuki , OGAWA, Shinya , TAKETO, Makoto , KAWADA, Kenji , HIRAI, Hideyo , SAKAI, Yoshiharu , MAEKAWA, Taira
IPC分类号: C07K16/28 , A61K39/395 , A61P29/00 , A61P35/00 , A61P37/02 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N5/12 , C12N15/13 , C12P21/08 , G01N33/53
摘要: An object of the present invention is to provide a monoclonal antibody which binds to a human CC chemokine receptor 1 (CCR1) and inhibits activation of the human CCR1, or an antibody fragment there of. The present invention relates to a monoclonal antibody which binds to an extracellular region of a human CCR1 and inhibits activation of the human CCR1 by a human CC chemokine ligand 15 (CCL15), or an antibody fragment thereof, a hybridoma producing the antibody, a nucleic acid having a nucleotide sequence encoding the antibody or the antibody fragment, a transformant cell containing a vector containing the nucleic acid, a method for producing the antibody or the antibody fragment using the hybridoma or the transformant cell; a therapeutic agent and a diagnostic agent containing the antibody or the antibody fragment, and a method for treating and diagnosing a CCR1-related disease using the antibody or the antibody fragment.
-
公开(公告)号:EP4353735A1
公开(公告)日:2024-04-17
申请号:EP22820270.1
申请日:2022-06-08
摘要: A synthetic adsorbent,
wherein a maximum value of a differential pore volume (mL/g) under a pressure condition of 0.5 psia to 30.0 psia, which is measured by the following method, is greater than 0.05 mL/g,
1. a pressure in a sample container where the synthetic adsorbent that has been dried is placed is reduced to 10 Pa or less, mercury specified in JIS K 8572 is degassed by reducing the pressure to 10 Pa or less, and the sample container is filled with the mercury at a pressure of 0.5 psia,
2. a mercury intrusion amount when the pressure in the sample container filled with the mercury is stepwisely increased from 0.5 psia to 30.0 psia is measured, and
3. a differential pore volume (mL/g) is determined by dividing an amount of an increase in the mercury intrusion amount when a first-stage pressure calculated based on the mercury intrusion amount measured in the item 2 is increased, by a measured amount of the synthetic adsorbent.-
公开(公告)号:EP2314686B2
公开(公告)日:2023-06-21
申请号:EP10180018.3
申请日:2001-10-05
-
公开(公告)号:EP3513809B1
公开(公告)日:2022-03-02
申请号:EP17850954.3
申请日:2017-09-13
-
公开(公告)号:EP3270923B1
公开(公告)日:2021-05-26
申请号:EP16765135.5
申请日:2016-03-18
发明人: HORITA, Takako
IPC分类号: A61K31/4439 , A61P25/00 , A61P25/16 , A61P25/28
-
公开(公告)号:EP3151859B1
公开(公告)日:2020-11-25
申请号:EP15806501.1
申请日:2015-05-29
发明人: KAKKIS, Emil , SAN MARTIN, Javier , SUDO, Tomohiro
IPC分类号: A61P19/08 , A61K39/395 , C07K14/50 , C07K16/22 , A61K39/00
-
公开(公告)号:EP3733693A1
公开(公告)日:2020-11-04
申请号:EP18897857.1
申请日:2018-12-27
摘要: The purpose of the present invention is to provide a novel IL-2 variant that has an improved selectivity for IL-2R αβγ and selectively activates Treg. The present invention pertains to: an IL-2 variant; a method for producing the IL-2 variant; a composition containing the IL-2 variant; a therapeutic agent for an immunological disease containing the IL-2 variant; a method for elevating the selectivity of IL-2 for IL-2R αβγ ; a method for improving the affinity of IL-2 for IL-2Rα subunit; a method for lowering the affinity of IL-2 for IL-2Rβ and/or γ subunits; and a method for selectively activating a regulatory T cell.
-
公开(公告)号:EP3698799A1
公开(公告)日:2020-08-26
申请号:EP18869094.5
申请日:2018-10-16
发明人: TOKUOKA Shinsuke , YOSHIDA Hayato , KONDO Yuichiro
IPC分类号: A61K31/785 , A61P3/00 , A61P13/12
摘要: The object of the present invention is to provide a therapeutic agent for hyperphosphatemia capable sufficiently decreasing a serum phosphorus concentration with a small dose. The present invention provides a therapeutic agent for hyperphosphatemia, which comprises, as an active ingredient, a particle containing certain crosslinked polymer (preferably crosslinked polyallylamine).
-
公开(公告)号:EP3594345A1
公开(公告)日:2020-01-15
申请号:EP18764304.4
申请日:2018-03-07
发明人: MASUDA, Kazuhiro , YAMADA, Yoji , IWAI, Hiroto , ISODA, Yuya , PIAO, Wen
IPC分类号: C12N15/113 , A61K31/713 , A61K48/00 , A61P7/02 , A61P9/10 , A61P13/12
摘要: The present invention provides a nucleic acid having activity to suppress expression of MASP2, a pharmaceutical composition comprising the nucleic acid, and a prophylactic or therapeutic drug containing the nucleic acid for autoimmune diseases such as APS, SLE and the like and thrombosis in hemodialysis.
-
-
-
-
-
-
-
-
-